NCT05271630Active, not recruiting
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 69 (actual)
- First submitted
- 28 Feb 2022
- Start date
- 20 Apr 2022
- Primary completion date
- 4 Dec 2025
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT05271630
What you commit to
- Study type: Observational
- Participants enrolled: 69
- From 20 Apr 2022 to the primary completion date, 4 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior evidence of disease progression
Other illness
- Patients who have other malignancy associated with a high risk of progression in the next 2 years.
Lab values
- Patients who have purely non-secretory multiple myeloma (i.e., the absence of a measurable protein in serum by electrophoresis and immunofixation and the absence of Bence-Jones protein in the urine defined by use of electrophoresis and immunofixation)
Who the study is looking for
- All MM patients (18 years or greater) receiving autologous transplantation given as first line therapy (Melphalan at least 140 mg/m2) will be screened and enrolled in the study if they qualify and willing to participate.
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
- Histologically confirmed diagnosis of multiple myeloma.
- Received high dose melphalan (≥ 140 mg/m2) followed by ASCT based on the institutional guidelines and within +60 and +180 after ASCT at the time of maintenance initiation.
- Disease status must be very good partial response (VGPR), complete remission (CR), or stringent complete remission (sCR) per IMWG response criteria at time of study entry.
- Measurable disease at diagnosis per IMWG criteria serum M spike ≥ 1g/dL, or Urine M protein ≥ 200 mg/24h or involved free light chain ≥ 100 mg/L with an abnormal ratio.
- Patients must have the Clonoseq ID sample showing a trackable clone in bone marrow.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.